XLS Consumer Health | Key figures € million Q2 – 2014 Q2 – 20131 Change in % Jan.–June 2014 Jan.–June 20131 Change in % 1 The previous year’s figures have been adjusted, see “The Merck Group and its divisions”. Total revenues 185.0 180.1 2.7 365.6 361.9 1.0 Sales 184.7 178.9 3.3 364.9 360.6 1.2 Operating result (EBIT) 36.9 34.2 7.9 73.7 71.0 3.8 Margin (% of sales) 20.0 19.1 20.2 19.7 EBITDA 39.3 36.5 7.6 78.4 76.0 3.3 Margin (% of sales) 21.3 20.4 21.5 21.1 EBITDA pre one-time items 41.4 35.5 16.7 82.6 74.8 10.5 Margin (% of sales) 22.4 19.8 22.6 20.7 Business free cash flow 36.2 50.9 –28.9 52.4 71.8 –27.0 Development of sales and results of [...]
With the publication of the results of 2013, Merck provided a forecast of expected sales, EBITDA pre one-time items and business free cash flow for the Merck Group and its divisions for 2014. Owing to business performance in the first half of 2014, Merck confirms its forecast for the full year 2014 despite anticipated negative foreign exchange effects. The latter will stem mainly from a significant drop in the value of the U.S. dollar and the Japanese yen, yet also from the Latin American currencies. Relative to the sales of the Merck Group, we therefore continue to assume negative exchange rate effects of approximately 3–4% compared to the previous year. Merck [...]
The Consumer Health division manufactures and markets over-the-counter pharmaceuticals. Consumer Health focuses on a number of well-known strategic brands, e.g. Neurobion®, Bion®3, Nasivin®, Femibion®, Seven Seas®, Sangobion®, Floratil®, Cebion®, Sedalmerck® and Kytta®. The division contributed 7% to Group sales and 5% to EBITDA pre one-time items (excluding Corporate and Other) in the second quarter of 2014. The division has high market penetration in Europe, Latin America as well as Southeast Asia. The division is also generating strong growth in Russia and Emerging Markets, particularly in India, Indonesia and Brazil, which have firmly established [...]
Merck Serono discovers, develops, manufactures and markets innovative pharmaceutical and biological prescription drugs to treat cancer, multiple sclerosis (MS), infertility, and growth disorders, as well as certain cardiovascular and metabolic diseases. As the company’s largest division, in the second quarter of 2014 Merck Serono generated 52% of Group sales and 51% of EBITDA pre one-time items (excluding Corporate and Other). The present Merck Serono division was formed in 2007 with the acquisition of the Swiss biopharmaceutical company Serono SA, which was integrated stepwise into Merck’s prescription drugs business. The former Serono headquarters in Geneva, [...]
[...] supplier of life science tools. In the second quarter of 2014, Merck Millipore contributed 23% to Group sales and 19% to EBITDA pre (excluding Corporate and Other). The majority of sales are generated by consumables. This enables the division to achieve recurring sales and stable, attractive cash flows. A highly diversified and loyal customer base additionally ensures a low risk profile. At the same time, Merck Millipore benefits from its broad portfolio and its global reach. Merck Millipore comprises three business areas: Bioscience, Lab Solutions and Process Solutions, as well as multiple specialized business fields. The main product groups of the Bioscience [...]
